Mehmet Akce

HCRN-GI23-621

A phase II study of pemigatinib plus durvalumab (MEDI4736) in previously treated advanced intrahepatic cholangiocarcinoma patients with FGFR-2 fusion or rearrangement
Status
Cancer Types
Liver and Bile Duct
Locations